Transcatheter aortic valve replacement in patients with aortic stenosis and cardiac amyloidosis.

ABSTRACT:

Background

Though the co-prevalence of aortic stenosis (AS) and cardiac amyloidosis (CA) is increasingly recognized, the role of transcatheter aortic valve replacement (TAVR) in patients with CA remains unclear.

Methods

The National Readmission Dataset (2016-18) and ICD-10 codes were used to identify those with CA and AS, in conjunction with TAVR status. The primary outcome was a composite of heart failure (HF) readmissions and all-cause mortality. All outcomes were followed up to 1-year with a median follow up time 172-days. Kaplan-Meier curves and multivariate cox-proportional hazard regression were used for time-to-event analysis.

Results

Of 1,127 CA patients, 92 (8.2%) had undergone TAVR. Patients with CA who received TAVR were younger and more commonly had corona

SUBMITTER: Khawaja T 

PROVIDER: S-EPMC8938882 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature